Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00511524 | An Imaging Study to Investigate the Distribution of GW842166X in the Brain. | PHASE1 | COMPLETED | 6 | — | — | Jun 26, 2007 | Jul 4, 2007 | Aug 7, 2017 | 1 | Sweden |
| Arm | Type | Description |
|---|---|---|
| Subjects receiving GW842166 | EXPERIMENTAL | Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive \[carbonyl-\^11C\]GW842166. |
| Name | Type | Description |
|---|---|---|
| GW842166X | DRUG | GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X. |
| [carbonyl-^11C]GW842166 | DRUG | \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution. |
Inclusion Criteria: * Male aged 50 to 80yrs inclusive at the screening visit. * subjects with negative HIV and hepatitis B and C test results within 3 months of study start. Exclusion Criteria: * A negative Allens test on arm to be used for arterial cannulation. * Any contraindications to MRI sca...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 3 | PHASE3 | Ziltivekimab B, Ziltivekimab C, Ziltivekimab, Semaglutide Pen Injector |
| AstraZeneca PLC | AZN | 1 | — | Undisclosed |
| Harvard Bioscience, Inc. | HBIO | 1 | — | Undisclosed |